Toboroz
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Conor H. O'Neill (principal investigator)
Toboroz
Family Communications After Genetic Testing
NCT07143487· Alliance for Clinical Trials in Oncology· Forrás
Contact: Sarah Spinette (principal investigator)
Fut, nem toboroz
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Rahul Anil (principal investigator)
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Toboroz
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Forrás
Contact: Misty J DeCaro
Fut, nem toboroz
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT06115499· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Aqeel A. Gillani (principal investigator)
Toboroz
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Steven Ades (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Kara K. Landry (principal investigator)
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Darci A. Gaiotti-Grubbs (principal investigator)
Fut, nem toboroz
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT05710406· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· 3. fázis· NRG Oncology· Forrás
Contact: Aqeel A. Gillani (principal investigator)
Toboroz
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· 2. fázis· NRG Oncology· Forrás
Contact: Nataniel H. Lester-Coll (principal investigator)
Toboroz
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Sarah Gillett (principal investigator)
Fut, nem toboroz
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Marie Wood, MD
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Charles Yun (principal investigator)
Fut, nem toboroz
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05092958· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04455750· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04579224· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT04625647· 2. fázis· SWOG Cancer Research Network· Forrás
Toboroz
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Christopher R. Mason (principal investigator)
Fut, nem toboroz
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· 3. fázis· NRG Oncology· Forrás
Toboroz
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
NCT04181060· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Aqeel A. Gillani (principal investigator)
Fut, nem toboroz
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
NCT04533451· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04310007· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
NCT04137107· 2/3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Conor H. O'Neill (principal investigator)
Toboroz
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Aqeel A. Gillani (principal investigator)
Fut, nem toboroz
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT04115631· 2. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT04094688· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Fut, nem toboroz
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· 3. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
NCT03793166· 3. fázis· National Cancer Institute (NCI)· Forrás
Showing 50 of 83.